SLBST Pharma is developing a non-hormonal therapy to treat endometriosis, a broadly prevalent disease with no cure and no effective therapies. We’ve identified a known immunomodulator, with a strong safety record, that shows promise in clinical studies as the first effective treatment for endometriosis. We have a green light from FDA to proceed with a Phase 2 dose-finding study. We hold issued and pending patents protecting this novel indication.

Patients are desperate for better treatment options. Over 4M women have been diagnosed with endometriosis, with two-thirds reporting significant functional impairment. There is no cure and current treatment options are bleak, skewing toward surgery and heavy use of opioids: three-quarters of patients undergo surgery (with nearly half opting for hysterectomy), one-third of patients take opioids, and one-in-ten patients take GnRH analogues, which chemically induce menopause. These options are expensive and none provide effective relief from the pain of endometriosis.

We've developed a reformulation of the well-known immunomodulator hydroxychloroquine (HCQ) that addresses endometriosis pathology at two points. It reduces pain by normalizing chronic inflammation and it inhibits lesion formation by reducing autophagy. Inflammation drives both pain sensitization and fibrosis, which causes adhesions. We’ve asked FDA to be indicated for relief of pain, as this is an established approval pathway which will allow us to get to market quickly.

SLBST Pharma

Org chart

Teams

Offices